Selected Milestones in Antiviral Drug Development
Viruses · 2024
DOI: 10.3390/v16020169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Erik De Clercq. Beteiligte Einrichtung: Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium. Hauptthemen laut MEDLINE: Anti-HIV Agents, Virus Diseases, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This review article will describe the (wide) variety of approaches that I envisaged to develop a specific therapy for viral infections: (i) interferon and its inducers, (ii) HSV, VZV and CMV inhibitors, (iii) NRTIs (nucleoside reverse transcriptase inhibitors), NtRTIs (nucleotide reverse transcriptase inhibitors) and NNRTIs (non-nucleoside reverse transcriptase inhibitors) as HIV inhibitors, (iv) NtRTIs as HBV inhibitors, and finally, (v) the transition of an HIV inhibitor to a stem cell mobilizer, as exemplified by AMD-3100 (Mozobil®).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.
ORCID-Profile: Erik De Clercq
Zitieren
APA
De Clercq, E. (2024). Selected Milestones in Antiviral Drug Development. Viruses. https://doi.org/10.3390/v16020169
Vancouver
De Clercq E. Selected Milestones in Antiviral Drug Development. Viruses. 2024. doi:10.3390/v16020169
BibTeX
@article{DeClercq2024,
author = {De Clercq, Erik},
title = {Selected Milestones in Antiviral Drug Development},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16020169}
}
EUVIMED